EcoDrugPlus

Histone Deacetylase 7-Like

Ensembl ID : ENSCGOG00000000212
Gene Symbol: LOC115008605
2 Cross references
197 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSCGOG00000019325
Gene Symbol: HCAR1
1 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSCGOG00000021538
Gene Symbol: HCN4
3 Cross references
210 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSCGOG00000015048
Gene Symbol: HCN4
3 Cross references
219 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSCGOG00000021131
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSCGOG00000003044
Gene Symbol: LOC115020805
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSCGOG00000014950
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSCGOG00000012728
Gene Symbol: IMPDH2
3 Cross references
202 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSCGOG00000019758
Gene Symbol: LOC115028167
3 Cross references
258 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSCGOG00000020698
Gene Symbol: LOC115009705
3 Cross references
259 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSCGOG00000018959
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSCGOG00000004785
Gene Symbol: IGF1R
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).